Onkológia 4/2024

Efficacy of darolutamide in the treatment castration sensitive prostate cancer

Castration sensitive prostate cancer is disease, in which treatment is mainly focused on adrogen deprivation, thus, testosteron level maintain in castration values. Darolutamide represents one of the novel androgen receptor signaling pathway inhibitor. This article propose darolutamide´s pharmacokinetics and pharmacodynamics. Moreover, article proposes current studies, which were outdone to evaluate efficacy of darolutamide in treatment of metastatic hormone sensitive prostate cancer. Additionally this article possess critical review of similar studies in order to evaluate efficacy of triplet combination in certain subpopulations of patients with castration sensitive prostate cancer.

Keywords: castration sensitive prostate cancer, darolutamide, treatment